Sai-Hong Ignatius Ou, MD, PhD, discusses the current landscapes of ROS1-positive and BRAF-mutant non–small cell lung cancer.
Original Article: Expert Discusses Potential Breakthroughs in ROS1+ and BRAF+ NSCLC